The Food & Drug Administration’s generic drug review activities are getting organizational status and a direct line to the top of FDA’s drug activities to reflect the new funding enacted by the FDA Safety & Innovation Act.
In a change announced September 7, Center for Drug Evaluation & Research Director Janet Woodcock made the generic review group...